Tuesday, 20 Mar 2018

Biologic/Novel Rx

Datesort ascending Type Title Save
12 Apr 2017 Social When BIOSIMILARS become available will PATIENTS use/accept them or switch to them? Survey for Patients, vote now>> https://t.co/nAp0aZYg0M
12 Apr 2017 Social PATIENTS - BIOSIMILAR Questions- a RheumNow survey on how they will affect you. Make your vote count! https://t.co/MYLcllgTac
12 Apr 2017 Social Looking for PATIENT Views on BIOSIMILAR BIOLOGIC Drugs - They're new, how will they affect you. Patients vote at>> https://t.co/tkXOvwzkpq
08 Apr 2017 Social RT @HealioRheum: Dr. William Rigby (@GeiselMed): The fact is, these JAKs work https://t.co/gN8Q1gBJVB https://t.co/XUv0OzHSVa
07 Apr 2017 Social Dr. Laura Cappelli - Talk on checkpoint inhibitors of PD-1 (nivolumab, pembrolizumab) and CTLA4 (impilimumab) commonly used in chemotherapy
06 Apr 2017 Social Dr Jon Kay - a biomarker is a measured indicator of biologic/pathogenic processes or drug responses to a therapeutic intervention #CCFsummit
04 Apr 2017 Social FDA grants "breakthrough status" (expedited review) for Rituximab in Pemphigus Vulgaris based on recent Lancet study https://t.co/c7JpzzmvgM
04 Apr 2017 News Abatacept Use During Surgery
04 Apr 2017 Social FDAs Oncology Advisory Committee votes 11-0 approve subcut rituximab for lymphoma & CLL. Given in minutes not hours https://t.co/MoYk8KFkTV
13 Mar 2017 Social Review of severe alopecia areata 90pts Rx w/ Xeljanz: 20% nearly total regrowth, 58% >50% regrowth,77% some regrowth https://t.co/8BZwOqevct
09 Mar 2017 News European Biologic Manufacturers Issue Warnings About Biosimilar Switching
07 Mar 2017 Social Placebo outperforms Anakinra (22% vs 8%) in 50 patients with chronic Fatigue Syndrome. IL-1 inhibition fails in CFS https://t.co/c1PW8aglhU
28 Feb 2017 Social Just like Oral Strategy Study (MTX+Tofa > Tofa) https://t.co/ReaHXaN5gK, DREAM registry shows TNFi + MTX > TNFi. https://t.co/2GiEfW1JJY
27 Feb 2017 News High Level Rheumatoid Responses to the GM-CSF inhibitor Mavrilimumab
23 Feb 2017 News Sirukumab Effective in Rheumatoid Arthritis
20 Feb 2017 News Abatacept Efficacy Giant Cell Arteritis
20 Feb 2017 Social Dr Mahadevan #RWCS17 ustekinumab has been approved for Crohns disease
17 Feb 2017 Social RT @DrRachelTate: No changes in safety, efficacy, or ab production in IFX vs inflectra. Eric Ruderman, MD & Arthur Kavanaugh, MD #rwcs2017…
17 Feb 2017 News Biosimilar Reports – February 2017
17 Feb 2017 Social Dr Kevin Winthrop at #RWCS2017 reviews DMARD/Biologic effects on vaccine responses. Most effected by RTX, least by… https://t.co/un74cCDo04